Cardiovasc Diabetol:与糖尿病前期个体发展成2型糖尿病风险相关的血浆载脂蛋白

2022-02-15 Nebula MedSci原创

血清apoE水平与糖尿病前期个体进展成2型糖尿病的风险呈正相关

目前,全世界约有4.63亿人患有糖尿病;据估计,到2030年时,全球糖尿病患者人数可能会增加到5.78亿。明确与2型糖尿病 (T2D) 风险相关的循环生物标志物有助于改善目前高危患者的预防策略。

本研究目的是评估随访期间糖尿病前期患者血浆载脂蛋白浓度与新发2型糖尿病发生率的相关性。

在IT-DIAB前瞻性研究中,307位空腹血糖水平受损的受试者(空腹血糖[FPG] 110-125 mg/dL)被随访了5年,每年随访1次。2型糖尿病发病定义:随访期间空腹血糖首次≥126 mg/dL。采用质谱分析载脂蛋白(apo)A-I、A-II、A-IV、B100、C-I, C-II、C-III、C-IV、D、E、F、H、J、L1、M和(a)血浆浓度。

研究流程

在随访的5年期间,共有115位受试者(37.5%)发展成了2型糖尿病。根据年龄、性别、体重指数、空腹血糖、HbA1c和他汀类药物使用情况进行调整后,apoC-I、apoC-II、apoC-III、apoE、apoF、apoH、apoJ和apoL1的血浆水平与2型糖尿病风险升高呈正相关。

根据基础apoE、apoF、apoJ或apoL1水平分组发生2型糖尿病的风险

根据血浆甘油三酯水平进展调整后,只有apoE、apoF、apoJ和apoL1仍与2型糖尿病的发病显著相关(1SD自然对数转换的风险比分别是:1.28[p=0.010]、1.22[p=0.037]、1.24[p=0.024]和1.26[p=0.014])。Kaplan–Meier生存曲线也提示,血清apoE水平低(<5.97 mg/dL)与空腹血糖受损进展成2型糖尿病的风险降低相关(p=0.002)。

总而言之,该研究结果表明,血清apoE水平与糖尿病前期个体进展成2型糖尿病的风险呈正相关,且独立于其他风险因素。此外,apoF、apoJ和apoL1与2型糖尿病风险的潜在相关性还需要进一步探究。

 

原始出处:

Croyal, M., Wargny, M., Chemello, K. et al. Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes. Cardiovasc Diabetol 21, 21 (2022). https://doi.org/10.1186/s12933-022-01452-5.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1640052, encodeId=69c0164005263, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Apr 25 22:15:23 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956349, encodeId=11cf1956349c3, content=<a href='/topic/show?id=a74d1109c8' target=_blank style='color:#2F92EE;'>#2型糖尿病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1109, encryptionId=a74d1109c8, topicName=2型糖尿病风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Sun Nov 13 14:15:23 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939316, encodeId=aab31939316f3, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Jul 08 20:15:23 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761841, encodeId=c52c1e618418a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Aug 09 12:15:23 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361310, encodeId=6f92136131032, content=<a href='/topic/show?id=2c509364ea9' target=_blank style='color:#2F92EE;'>#载脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93647, encryptionId=2c509364ea9, topicName=载脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Wed Feb 16 14:15:23 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424826, encodeId=347d14248261c, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Feb 16 14:15:23 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193681, encodeId=998c11936811a, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=066c2128345, createdName=1351fc2f66m, createdTime=Tue Feb 15 18:15:04 CST 2022, time=2022-02-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1640052, encodeId=69c0164005263, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Apr 25 22:15:23 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956349, encodeId=11cf1956349c3, content=<a href='/topic/show?id=a74d1109c8' target=_blank style='color:#2F92EE;'>#2型糖尿病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1109, encryptionId=a74d1109c8, topicName=2型糖尿病风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Sun Nov 13 14:15:23 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939316, encodeId=aab31939316f3, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Jul 08 20:15:23 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761841, encodeId=c52c1e618418a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Aug 09 12:15:23 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361310, encodeId=6f92136131032, content=<a href='/topic/show?id=2c509364ea9' target=_blank style='color:#2F92EE;'>#载脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93647, encryptionId=2c509364ea9, topicName=载脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Wed Feb 16 14:15:23 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424826, encodeId=347d14248261c, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Feb 16 14:15:23 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193681, encodeId=998c11936811a, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=066c2128345, createdName=1351fc2f66m, createdTime=Tue Feb 15 18:15:04 CST 2022, time=2022-02-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1640052, encodeId=69c0164005263, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Apr 25 22:15:23 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956349, encodeId=11cf1956349c3, content=<a href='/topic/show?id=a74d1109c8' target=_blank style='color:#2F92EE;'>#2型糖尿病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1109, encryptionId=a74d1109c8, topicName=2型糖尿病风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Sun Nov 13 14:15:23 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939316, encodeId=aab31939316f3, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Jul 08 20:15:23 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761841, encodeId=c52c1e618418a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Aug 09 12:15:23 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361310, encodeId=6f92136131032, content=<a href='/topic/show?id=2c509364ea9' target=_blank style='color:#2F92EE;'>#载脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93647, encryptionId=2c509364ea9, topicName=载脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Wed Feb 16 14:15:23 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424826, encodeId=347d14248261c, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Feb 16 14:15:23 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193681, encodeId=998c11936811a, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=066c2128345, createdName=1351fc2f66m, createdTime=Tue Feb 15 18:15:04 CST 2022, time=2022-02-15, status=1, ipAttribution=)]
    2022-07-08 quxin068
  4. [GetPortalCommentsPageByObjectIdResponse(id=1640052, encodeId=69c0164005263, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Apr 25 22:15:23 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956349, encodeId=11cf1956349c3, content=<a href='/topic/show?id=a74d1109c8' target=_blank style='color:#2F92EE;'>#2型糖尿病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1109, encryptionId=a74d1109c8, topicName=2型糖尿病风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Sun Nov 13 14:15:23 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939316, encodeId=aab31939316f3, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Jul 08 20:15:23 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761841, encodeId=c52c1e618418a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Aug 09 12:15:23 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361310, encodeId=6f92136131032, content=<a href='/topic/show?id=2c509364ea9' target=_blank style='color:#2F92EE;'>#载脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93647, encryptionId=2c509364ea9, topicName=载脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Wed Feb 16 14:15:23 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424826, encodeId=347d14248261c, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Feb 16 14:15:23 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193681, encodeId=998c11936811a, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=066c2128345, createdName=1351fc2f66m, createdTime=Tue Feb 15 18:15:04 CST 2022, time=2022-02-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1640052, encodeId=69c0164005263, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Apr 25 22:15:23 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956349, encodeId=11cf1956349c3, content=<a href='/topic/show?id=a74d1109c8' target=_blank style='color:#2F92EE;'>#2型糖尿病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1109, encryptionId=a74d1109c8, topicName=2型糖尿病风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Sun Nov 13 14:15:23 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939316, encodeId=aab31939316f3, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Jul 08 20:15:23 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761841, encodeId=c52c1e618418a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Aug 09 12:15:23 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361310, encodeId=6f92136131032, content=<a href='/topic/show?id=2c509364ea9' target=_blank style='color:#2F92EE;'>#载脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93647, encryptionId=2c509364ea9, topicName=载脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Wed Feb 16 14:15:23 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424826, encodeId=347d14248261c, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Feb 16 14:15:23 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193681, encodeId=998c11936811a, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=066c2128345, createdName=1351fc2f66m, createdTime=Tue Feb 15 18:15:04 CST 2022, time=2022-02-15, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1640052, encodeId=69c0164005263, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Apr 25 22:15:23 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956349, encodeId=11cf1956349c3, content=<a href='/topic/show?id=a74d1109c8' target=_blank style='color:#2F92EE;'>#2型糖尿病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1109, encryptionId=a74d1109c8, topicName=2型糖尿病风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Sun Nov 13 14:15:23 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939316, encodeId=aab31939316f3, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Jul 08 20:15:23 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761841, encodeId=c52c1e618418a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Aug 09 12:15:23 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361310, encodeId=6f92136131032, content=<a href='/topic/show?id=2c509364ea9' target=_blank style='color:#2F92EE;'>#载脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93647, encryptionId=2c509364ea9, topicName=载脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Wed Feb 16 14:15:23 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424826, encodeId=347d14248261c, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Feb 16 14:15:23 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193681, encodeId=998c11936811a, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=066c2128345, createdName=1351fc2f66m, createdTime=Tue Feb 15 18:15:04 CST 2022, time=2022-02-15, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1640052, encodeId=69c0164005263, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Apr 25 22:15:23 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956349, encodeId=11cf1956349c3, content=<a href='/topic/show?id=a74d1109c8' target=_blank style='color:#2F92EE;'>#2型糖尿病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1109, encryptionId=a74d1109c8, topicName=2型糖尿病风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Sun Nov 13 14:15:23 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939316, encodeId=aab31939316f3, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Jul 08 20:15:23 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761841, encodeId=c52c1e618418a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Aug 09 12:15:23 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361310, encodeId=6f92136131032, content=<a href='/topic/show?id=2c509364ea9' target=_blank style='color:#2F92EE;'>#载脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93647, encryptionId=2c509364ea9, topicName=载脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Wed Feb 16 14:15:23 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424826, encodeId=347d14248261c, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Feb 16 14:15:23 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193681, encodeId=998c11936811a, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=066c2128345, createdName=1351fc2f66m, createdTime=Tue Feb 15 18:15:04 CST 2022, time=2022-02-15, status=1, ipAttribution=)]
    2022-02-15 1351fc2f66m

    谢谢

    0

相关资讯

亚洲人群研究:豆制品抗糖尿病大赛结果出炉!水煮大豆、豆腐和味噌中,谁可将糖尿病风险打对折?

2019年全球糖尿病患者达4.63亿人。预计增长51%,到2030年将达到5.78亿,到2045年将达到7亿。

如果你愿意一杯两杯三杯地喝牛奶补钙,2型糖尿病风险或可降低7%、14%、23%!

Scientifc Reports:膳食钙摄入量与成人2型糖尿病和高血糖的关系:一项系统性综述和流行病学研究的剂量-反应荟萃分析

Lancet子刊:每6秒钟就有一个人因糖尿病死亡,提高收入可以降低死亡风险吗?

全世界每6秒钟就有一个人因糖尿病死亡,中国的糖尿病患者人数已经位居全球第一。

Clin Gastroenterology H: PNPLA3多态性降低了非酒精性脂肪肝患者患糖尿病的易感性

非酒精性脂肪性肝病(NAFLD)是指除外酒精和其他明确的损肝因素所致的肝细胞内脂肪过度沉积为主要特征的临床病理综合征,与胰岛素抵抗和遗传易感性密切相关的获得性代谢应激性肝损伤。

Nature Medicine:安全有效!邓宏魁等通过人多能干细胞来源的胰岛细胞治疗糖尿病

研究首先在原有工作基础上进一步优化和改进了人多能干细胞向胰岛细胞的分化制备方案,获得了功能成熟的人多能干细胞分化来源的胰岛细胞;进一步将其移植入非人灵长类糖尿病动物模型中,系统评价了人多能干细胞分化的

绝了!1种微量元素&1种调味品,单or联用都能改善糖尿病前期患者的血脂!

Diabetology & Metabolic Syndrome:姜黄素和锌的联合补充以及减肥饮食可以改善糖尿病前期患者的血脂状况:一项多组、平行组、随机、双盲安慰剂对照2期临床试验。